Genta is committed to identifying, developing and commercializing innovative new products to treat patients with cancer and to  address  the unmet medical needs of those afflicted with this disease.  The shareholders of Genta Incorporated are key partners in this endeavor, and we are very grateful for your investment and confidence in the Company.  Genta is committed to keeping our shareholders apprised of new developments from our Company, and we value regular and timely communication with individuals and institutions who own our shares.
 
Genta recommends that shareholders register to receive (via email or fax) the latest Company news and press releases. Please register here.

To contact Genta Investor Relations, please send your inquiries via email to or phone 908-286-3980.